Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.) [Internet]

Review
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb.

Excerpt

The objective of this report was to perform a systematic review of the beneficial and harmful effects of sucroferric oxyhydroxide to control serum phosphorus levels in adult patients with end-stage renal disease on dialysis.

Publication types

  • Review

Grants and funding

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.